Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms;Impacto clínico de la cuantificación de la carga mutacional de JAK2V617F en pacientes con neoplasias mieloproliferativas crónicas Ph negativas clásicas

Medicina Clinica

Volumn 139, Issue 9, 2012, Pages 373-378

  Kerguelén Fuentes, Ana Esther ^a   Hernández Maraver, Dolores ^a   Lombardia, Luis ^b   Canales Albendea, Miguel Angel ^a   Rodriguez De La Rúa, Ana ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

Diagnosis; Homozygote; Janus Kinase; Leukocytosis; Myeloproliferative disorders; Philadelphia chromosome; Prognosis; Splenomegaly; Thrombosis

Indexed keywords

ARTERY THROMBOSIS; ARTICLE; GENE; GENE MUTATION; HEMATOPOIESIS; HUMAN; JANUS KINASE 2 GENE; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NEUTROPHIL; PHENOTYPE; POLYCYTHEMIA VERA; REAL TIME POLYMERASE CHAIN REACTION; SPLENOMEGALY; THROMBOCYTHEMIA;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENETIC MARKERS; HETEROZYGOTE; HOMOZYGOTE; HUMANS; JANUS KINASE 2; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; POINT MUTATION; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84866732944     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2012.03.032     Document Type: Article

References (30)

1. C. James, V. Ugo, J.P. Le Couédic, J. Staerk, F. Delhommeau, and C. Lacout A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 2005 1144 1148
2. R. Kralovics, F. Passamonti, A.S. Buser, S.S. Teo, R. Tiedt, and J.R. Passweg A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 2005 1779 1790
3. J.W. Vardiman, J. Thiele, D.A. Arber, R.D. Brunning, M.J. Borowitz, and A. Porwit The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 2009 937 951
4. A. Tefferi, G. Barosi, R.A. Mesa, F. Cervantes, H.J. Deeg, J.T. Reilly IWG for Myelofibrosis Research and Treatment (IWG-MRT) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT) Blood 108 2006 1497 1503
5. F. Cervantes, B. Dupriez, A. Pereira, F. Passamonti, J.T. Reilly, and E. Morra New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Blood 113 2009 2895 2901
6. K.J. Livak Allelic discrimination using fluorogenic probes and the 5' nuclease assay Genet Anal 14 1999 143 149
7. R. Scherber, A.C. Dueck, P. Johansson, T. Barbui, G. Barosi, and A.M. Vannucchi The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients Blood 118 2011 401 408
8. A.F. Remacha, G. Puget, J.F. Nomdedéu, C. Estivill, M.P. Sardà, and C. Canals [Evaluation of V617F mutation of JAK2 in negative chromosome Philadelphia chronic myeloproliferative disorders] Med Clin (Barc) 127 2006 601 604
9. A. Tefferi, P. Noel, and C.A. Hanson Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology J Mol Diagn 13 2011 461 466
10. F. Passamonti, C. Elena, S. Schnittger, R.C. Skoda, A.R. Green, and F. Girodon Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations Blood 117 2011 2813 2816
11. A. Tefferi Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy Am J Hematol 83 2008 491 497
12. F. Passamonti, E. Rumi, D. Pietra, C. Elena, E. Boveri, and L. Arcaini A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications Leukemia 24 2010 1574 1579
13. A. Pardanani, J.R. Gotlib, C. Jamieson, J.E. Cortes, M. Talpaz, and R.M. Stone Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis J Clin Oncol 29 2011 789 796
14. A. Carobbio, E. Antonioli, P. Guglielmelli, A.M. Vannucchi, F. Delaini, and V. Guerini Leukocytosis and risk stratification assessment in essential thrombocythemia J Clin Oncol 26 2008 2732 2736
15. F. Passamonti, E. Rumi, M. Caramella, C. Elena, L. Arcaini, and E. Boveri A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis Blood 111 2008 3383 3387
16. F. Passamonti, E. Rumi, C. Pascutto, M. Cazzola, and M. Lazzarino Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia J Thromb Haemost 7 2009 1587 1589
17. A. Carobbio, J. Thiele, F. Passamonti, E. Rumi, M. Ruggeri, and F. Rodeghiero Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients Blood 117 2011 5857 5859
18. M.L. Randi, E. Ruzzon, F. Tezza, M. Scapin, E. Duner, and R. Scandellari JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia Aging Clin Exp Res 23 2011 17 21
19. I.J. Dahabreh, K. Zoi, S. Giannouli, C. Zoi, D. Loukopoulos, and M. Voulgarelis Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia Leuk Res 33 2009 67 73
20. F. Lussana, S. Caberlon, C. Pagani, P.W. Kamphuisen, H.R. Büller, and M. Cattaneo Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review Thromb Res 124 2009 409 417
21. A.M. Vannucchi, E. Antonioli, P. Guglielmelli, G. Longo, A. Pancrazzi, and V. Ponziani Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden Leukemia 21 2007 1952 1959
22. P.J. Campbell, L.M. Scott, G. Buck, K. Wheatley, C.L. East, and J.T. Marsden Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study Lancet 366 2005 1945 1953
23. A.M. Vannucchi, E. Antonioli, P. Guglielmelli, A. Rambaldi, G. Barosi, and R. Marchioli Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia Blood 110 2007 840 846
24. A. Alvarez-Larrán, B. Bellosillo, L. Martínez- Avilés, S. Saumell, A. Salar, and E. Abella Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients Br J Haematol 146 2009 504 509
25. J.L. Spivak Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry Semin Hematol 40 1 Suppl 1 2003 1 5
26. A.L. Basquiera, N.W. Soria, R. Ryser, M. Salguero, B. Moiraghi, and F. Sackmann Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders Hematology 14 2009 323 330
27. R.A. Mesa, H. Powell, T. Lasho, G. Dewald, R. McClure, and A. Tefferi JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia Leuk Res 30 2006 1457 1460
28. A. Tefferi Essential thrombocythemia: scientific advances and current practice Curr Opin Hematol 13 2006 93 98
29. P. Guglielmelli, G. Barosi, G. Specchia, A. Rambaldi, F. Lo Coco, and E. Antonioli Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele Blood 114 2009 1477 1483
30. F. Cervantes, F. Passamonti, and G. Barosi Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders Leukemia 22 2008 905 914.